Biomedicine Daily · Tuesday, 29 September 2026
CBA FRONTIER INSIGHTS
Ivonescimab Becomes First Drug to Beat Pembrolizumab on Overall Survival in Lung Cancer
Ivonescimab extended median overall survival to 30.8 months versus 22.6 months for pembrolizumab as first-line treatment of PD-L1-positive (TPS ≥1%) advanced non-small cell lung cancer, cutting the risk of death by 27%. Data presented by Caicun Zhou of Shanghai East Hospital at WCLC make ivonescimab the first drug to top pembrolizumab head-to-head in a phase 3 trial with positive results on both progression-free and overall survival, a landmark for the bispecific antibody field and a direct challenge to Merck's checkpoint inhibitor franchise. The day also brought FDA approvals for the first oral RAS-targeted drug in pancreatic cancer, a first therapy for warm autoimmune hemolytic anemia, and a third treatment for fibrodysplasia ossificans progressiva, plus Kodiak's Eylea-matching wet AMD data that more than doubled its shares.
Clinical readouts and safety
Ivonescimab Beats Pembrolizumab on Overall Survival in Frontline PD-L1-Positive Advanced NSCLC
Ivonescimab extended median overall survival to 30.8 months versus 22.6 months for pembrolizumab in first-line treatment of PD-L1-positive (TPS ≥1%) advanced non-small cell lung cancer, cutting the risk of death by 27%. Data presented by Caicun Zhou of Shanghai East Hospital at the 2024 WCLC make ivonescimab the first drug to beat pembrolizumab head-to-head in a phase 3 trial with positive results on both progression-free and overall survival.
mRNA-Encoded CD19×CD3 T-Cell Engager ABO2203 Drives Complete Remission in 3 Refractory Secondary ITP Patients
An mRNA-encoded CD19×CD3 T-cell engager, ABO2203, achieved complete remission within one month in all 3 treated patients with refractory secondary ITP, and the responses held through 6 months of follow-up. The patients had systemic lupus erythematosus, Sjögren's syndrome, or antiphospholipid syndrome and had failed steroids, immunosuppressants, TPO-RA, and telitacicept. The work, from Ruijin Hospital and Abogen Biosciences, published in Cell.
[Articles] Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial
Garetosmab, an activin A-blocking antibody, substantially reduced the number of new heterotopic bone lesions in patients with fibrodysplasia ossificans progressiva in the randomised, double-blind, placebo-controlled phase 3 OPTIMA trial. The results support its potential as an efficacious and generally well tolerated disease-modifying therapy for FOP.
Kodiak skyrockets on positive study data for 2 eye drugs
Kodiak Sciences' Zenkuda matched Regeneron's Eylea in a Phase 3 trial in wet age-related macular degeneration, improving visual acuity by 7.2 letters versus 7.6 for Eylea, with 54% of participants dosed only once every six months under an individualized strategy. Tabirafusp alfa tedromer was also non-inferior, gaining 6.3 letters. Kodiak shares more than doubled and its market value rose by more than $3 billion; an FDA filing for Zenkuda is planned in the fourth quarter of 2026.
Kodiak challenges Eylea with a six-month dosing interval in wet AMD
Zenkuda tarcocimab tedromer met the primary endpoint in the Phase III DAYBREAK study in wet AMD, showing non-inferiority to Eylea aflibercept on best corrected visual acuity at one year. More than half of patients reached a six-month dosing interval, a point of differentiation in retinal disease, and Kodiak Sciences shares rose 178% on the news.
An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus
Adicet's donor-derived gamma delta CAR-T therapy prula-cel drove lupus into remission in an early-stage trial. After a year of follow-up, 50% of evaluable lupus nephritis patients had a complete kidney response and 54% met criteria for remission, with all stopping immunosuppressive drugs and no serious cytokine release syndrome or neurological side effects. A pivotal lupus study is planned for the fourth quarter.
Regulatory and policy
FDA Approves Daraxonrasib as First Oral RAS-Targeted Drug for Pancreatic Cancer
The FDA approved Rasonque (daraxonrasib) on August 26, 2026 for metastatic pancreatic adenocarcinoma in patients previously treated with at least one systemic therapy. It is the first direct RAS-targeted oral drug approved in pancreatic cancer, a disease where more than 90% of patients carry KRAS mutations. The approval comes 44 years after RAS was identified as the first human oncogene in 1982.
FDA Approves Merck and Eisai's Belzutifan Plus Lenvatinib for Advanced Clear Cell Renal Cell Carcinoma
The US FDA has approved belzutifan combined with lenvatinib, from Merck and Eisai, for adults with advanced clear cell renal cell carcinoma previously treated with a PD-1/PD-L1 inhibitor. The companies say it is the first approved regimen pairing a HIF-2α inhibitor with a multi-target VEGFR-TKI in this setting. Belzutifan, developed by Merck, was the first approved HIF-2α inhibitor and blocks the HIF-2α signalling pathway.
FDA Approves FcRn Blocker Nipocalimab as First Drug for wAIHA
The FDA approved nipocalimab on August 25 for adults and adolescents aged 12 and older with warm autoimmune hemolytic anemia who are receiving or have received corticosteroid treatment, making it the first approved therapy in this indication. Nipocalimab is an immunoselective neonatal Fc receptor blocker that lowers circulating IgG, including the autoantibodies driving wAIHA. Its pivotal phase II/III ENERGY trial, a 24-week randomized double-blind study published in Blood, evaluated efficacy and safety in these patients.
EU Withdraws Marketing Authorisation for Hansoh's Aumseqa Less Than Eight Months After Approval
The European Commission's Directorate-General for Health and Food Safety has withdrawn the EU marketing authorisation for Hansoh Pharmaceutical's aumolertinib tablets, marketed overseas as Aumseqa. The decision, dated September 25, concerns the use of osimertinib clinical data in the marketing application. The drug had been approved on February 12, 2026, less than eight months earlier, and Hansoh says it will resubmit the application as soon as possible.
FDA Approves First Treatment for MCT8 Deficiency
The FDA approved Emcitate (tiratricol) oral suspension, from Egetis Therapeutics US Inc., for peripheral thyrotoxicosis in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. It is the first FDA-approved therapy for the rare genetic disease, which mainly affects males. Evidence came from a randomized placebo-controlled trial (NCT05579327) and a longer-term open-label study spanning infants to adults. The once-daily liquid can be given by mouth or feeding tube.
Japan Approves World's First iPSC-Derived Regenerative Medicine Product for Parkinson's Disease
Japan has approved the world's first regenerative medicine product derived from induced pluripotent stem cells (iPSC) for treating Parkinson's disease. The milestone comes two decades after Shinya Yamanaka reprogrammed fibroblasts back to a blank state in 2006, with iPSC-derived cells now being implanted into patients' brains. Parkinson's becomes the first neurological field where the technology has broken through.
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease
The FDA approved Mirum Pharmaceuticals' zilurgisertib, to be marketed as Atebrioz, for fibrodysplasia ossificans progressiva in patients 12 years and older, making it the third FOP treatment after Ipsen's Sohonos (August 2023) and Regeneron's Pasatru. The once-daily ALK2 inhibitor, which Mirum gained full ownership of in April after licensing from Incyte, showed an 81% reduction in new lesion volume and 99% reduction in total volume versus placebo at 24 weeks in the Phase 2 PROGRESS study, with effects maintained through week 48. Mirum is now conducting trials in children as young as 2 years.
FDA advisers split 6-4 on Grail's multi-cancer early detection test Galleri
On September 23, an FDA advisory panel of 10 experts voted 6-4 on Grail's multi-cancer early detection test Galleri. Galleri has been offered in the US as an LDT since mid-2021, with nearly 600,000 tests sold by the end of June 2026 and screening revenue of $42.6 million in the second quarter of 2026 alone. The panel's divided vote precedes further FDA consideration of the test.
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
Merck & Co. and Daiichi Sankyo withdrew their U.S. application for accelerated approval of ifinatamab deruxtecan, or I-DXd, in extensive-stage small-cell lung cancer after the FDA indicated Phase 2 response rate data were insufficient; a decision had been expected by Oct. 10. The B7-H3-targeting drug is still being tested against chemotherapy in relapsed disease, a trial in which recruitment was temporarily halted last year after higher than anticipated deaths from a serious lung condition. Competing B7-H3 drugs licensed to GSK (riz-rez) and Roche (tam-peli) have advanced, and I-DXd is also in Phase 3 testing in prostate cancer and esophageal squamous cell carcinoma.
Industry and deals
Merck turns to China-based SciBrunch for KRAS program, pays $400M up front: Deals Report
Merck & Co. has licensed global rights to SPR2015, a preclinical KRAS G12D molecular glue inhibitor from China-based SciBrunch, paying $400 million up front. The deal follows reported failed M&A negotiations with Revolution Medicines in the $30 billion range, after that company reported in April that daraxonrasib led to a survival benefit in pancreatic cancer patients. Further deal terms for the SciBrunch agreement were not disclosed.
Merck Licenses Chinese Firm Sipurui's Oral KRAS G12D Inhibitor SPR2015 in Deal Worth Up to $2.13 Billion
Chinese drug developer Sipurui has granted Merck exclusive worldwide rights to develop, manufacture and commercialize SPR2015, an investigational oral KRAS G12D (ON) inhibitor. Sipurui receives an upfront payment of $400 million and is eligible for development, commercialization and other milestone payments tied to multiple indications, bringing the deal's total potential value to up to $2.13 billion.
SciBrunch Therapeutics Licenses Oral KRAS G12D(ON) Inhibitor SPR2015 to Merck Sharp & Dohme
SciBrunch Therapeutics (Shanghai) has granted Merck Sharp & Dohme a global exclusive licence for SPR2015, a preclinical oral KRAS G12D(ON) inhibitor. SciBrunch will receive $400 million upfront and is eligible for milestone payments tied to development, commercialisation and other activities across multiple indications. The company focuses on RAS-pathway therapies for pancreatic, colorectal and lung cancers.
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
Merck has licensed exclusive global rights to SciBrunch Therapeutics' preclinical oral KRAS G12D (ON) inhibitor SPR2015, paying $400 million upfront with milestone payments that could bring the total to $2.13 billion. The deal has closed, and Merck recorded a pre-tax charge of $400 million, about 13 cents per share, in Q3. SciBrunch expects SPR2015 to enter human trials by the end of this year. The same day, Merck and Daiichi Sankyo withdrew an accelerated approval request for ifinatamab deruxtecan in extensive-stage small cell lung cancer after the FDA said the data did not support the filing.
Research papers
medicalxpress.comA missing piece in the cell death and inflammation signaling pathway puzzle has been revealed
The E3 ubiquitin ligase HERC4 is the switch that converts TNF signaling from cell survival to cell death. HERC4 binds kinase-active RIPK1 in Complex I, ubiquitinates it, and initiates formation of Complex II (RIPK1, RIPK3, FADD, caspase-8, cFLIP), which drives apoptosis or necroptosis. Mice lacking HERC4 were protected against TNF-induced systemic inflammation and acute liver damage, marking HERC4 as a candidate drug target for rheumatoid arthritis, IBD, psoriasis, sepsis and some cancers.
Pathway-wide base editing charts chemical-genetic interactions in MAPK signaling
Base editor scanning across 22 MAPK genes, performed under pathway hyperactivation or inhibition at various nodes, produced a chemical-genetic interaction map of the RAS-RAF-MEK-ERK cascade. Drug resistance mutations often arose in proteins other than the direct drug target, catalytically impaired CRAF mutants gave bidirectional resistance and sensitization to structurally similar MEK inhibitors, and an allosteric site was found in the KRAS N-terminus. The work establishes BE scanning as a scalable method for network-level chemical-genetic mapping in a major oncogenic pathway.
Disruption of the ARID1A-containing SWI/SNF complex reprograms tumor-associated macrophages and enhances immunotherapy response
Disrupting the SWI/SNF chromatin remodeling complex in tumor-associated macrophages reprograms them and improves checkpoint blockade immunotherapy. Pharmacologic inhibition of SWI/SNF ATPase activity slowed tumor growth, and deleting the SWI/SNF subunit Arid1a in myeloid cells was sufficient to suppress tumor progression and enhance checkpoint blockade response. The reprogramming involved reduced enhancer accessibility at poor-prognosis genes such as Spp1, increased accessibility at interferon-stimulated gene promoters, elevated CD86, and required CD86 costimulation and CD8+ T cells.
Fibroblasts Restrain Gut Inflammation Through IGF1-Dependent Regulation of Innate Lymphocytes
Gut fibroblasts restrain intestinal inflammation through a previously undescribed mechanism. Teams from Shanghai Jiao Tong University and Tsinghua University report in Science that fibroblast-secreted insulin-like growth factor 1 (IGF1) controls CXCL10 expression in group 3 innate lymphoid cells (ILC3), which limits the recruitment of plasmacytoid dendritic cells (pDC) and thereby suppresses gut inflammation. The finding identifies IGF1 signaling as a new target for inflammatory bowel disease.
m6A-Driven Intratumoral Cholesterol Biosynthesis Fuels Castration-Resistant Prostate Cancer Progression
A METTL3–NUP93 interaction couples m6A-mediated nuclear mRNA export to cholesterol biosynthesis, driving castration-resistant prostate cancer. Overexpression of wild-type METTL3 or NUP93, but not enzymatically dead METTL3 or the METTL3-interaction-deficient NUP93 mutant, raised intracellular androgens, activated AR signaling under castrate conditions, and promoted androgen-independent growth in vitro and in vivo. Pharmacological inhibition of METTL3 or targeted demethylation of mRNAs encoding cholesterol biosynthesis enzymes suppressed CRPC malignancy.
medicalxpress.comMetabolic activity of gut bacteria can either promote or inhibit function of CAR T cells in cancer therapy
Microbial metabolites, not just gut bacterial composition, determine whether CAR T-cell therapy succeeds: in a cohort of 129 patients across three German university hospitals, specific metabolites correlated with response or failure. Low pre-treatment valerate predicted higher risk of disease progression, while indole-3-carboxaldehyde and indole-3-acetic acid were linked to unfavorable outcomes and reduced CAR T-cell efficacy in human and mouse models. A metabolite-based risk score predicted clinical response, and the team is preparing the CARBiome trial of microbiota transfer in multiple myeloma patients.
Structural polymorphism and population-variable coding capacity of HERV-K(HML-2) in human pangenomes
Haplotype-resolved long-read assemblies from 292 donors reveal extensive structural polymorphism in HERV-K(HML-2) proviruses: tandem arrays at 13 loci with up to six copies each, a previously undescribed full-length provirus at 8q11.23, and intact open reading frames in many individuals where reference genomes carry disruptive mutations. Short-read genotyping left 32.5% of donor-variant pairs unresolved at sites tied to viral reading frames. HML-2 expression studies should account for the coding alleles each individual carries.
BLTP3A dysfunction unleashes lysosomal stress-induced antitumor immunity through STING
A common germline missense variant in BLTP3A, M1098T, impairs lysosomal stress resolution in high-grade serous ovarian cancer, prolonging STING activity and tumor-derived IFN-λ. Patients carrying M1098T had longer overall survival and tumors enriched for cytotoxic T cell-myeloid neighborhoods. In syngeneic tumors, Bltp3a loss or the orthologous variant delayed progression and generated Cxcl9+ antigen-presenting macrophage niches, with tumor-cell STING and IFN-λ required for immune remodeling and tumor control.
A meiotic B-type cyclin selectively drives mitotic progression and fidelity in cancer cells
Cyclin B3, previously thought to act only in female meiosis, is expressed in mitotic cells and partners with CDK1 and CDK2 to drive timely mitotic progression through proper chromosome alignment and stable kinetochore-microtubule interactions. Depleting cyclin B3 disrupted mitosis in most cancer cell lines tested, including colorectal, osteosarcoma, and breast cancer models, while non-transformed cells were largely unaffected. Phospho-mass spectrometry identified kinetochore and mitotic spindle components as substrates, pointing to a preferential cancer-cell dependency.
A druggable chromatin vulnerability in suppressive neutrophils restores antitumor immunity
Suppressive neutrophils (PMN-MDSCs) depend on mSWI/SNF chromatin remodeling to maintain their identity, and two orally bioavailable mSWI/SNF ATPase antagonists, a degrader and a catalytic inhibitor, produced immune-dependent tumor control in syngeneic models, including tumors resistant to PD-1 blockade. Treatment depleted intratumoral PMN-MDSCs, restored functional CD8+ T cells, enhanced checkpoint therapy without overt toxicity, and blocked PMN-MDSC expansion in mouse and human cells. Mechanistically, antagonism collapsed chromatin accessibility and PU.1/C/EBPβ occupancy at regulatory elements sustaining PMN-MDSC identity.
Glutamine and GLS1 are key metabolic checkpoints that Limit T cell Infiltration and Function in HNSCC
Glutaminase-1 acts as a metabolic checkpoint limiting T cell infiltration and function in head and neck squamous cell carcinoma (HNSCC). Pharmacologic inhibition or genetic deletion of glutaminase-1 increased tumor susceptibility to immune cell-mediated cytotoxicity and sensitized patient-derived tumor fragments to immune checkpoint blockade, via disruption of glutathione-dependent ROS defense, impaired tumor proliferation, and increased MHC expression. Breast cancer fragments, which show low glutaminase-1 expression, were not responsive, supporting patient stratification for metabolism-targeted immunotherapy.
medicalxpress.comBlocking immune cells' path into the brain limits neurodegeneration
Blocking the CXCR3 receptor kept T cells out of the brains of mice with Alzheimer's-like tau accumulation. Mice injected with an anti-CXCR3 antibody every five days for three and a half months had about half as many brain T cells, preserved roughly 40% more tissue in memory centers, and performed better on a memory test, with tau levels unchanged. The antibody acted at the brain border without entering brain tissue, pointing to a T-cell-targeted route against tauopathies that anti-amyloid drugs do not cover.
Systemic tumor-cell reprogramming converts solid tumors into in situ biofactories for immunotherapy
LENTRA, an antigen-targeted lentiviral platform, genetically reprograms tumor cells in vivo to produce therapeutic proteins directly within the tumor after intravenous administration. In multiple murine solid tumor models, tumor-restricted expression of anti-CTLA-4 or IL-12 triggered potent antitumor responses without systemic toxicities, while sialidase secretion drove dendritic cell and T cell infiltration, macrophage reprogramming, tumor regression and durable immune memory. LENTRA also mediated efficient transduction, immune remodeling and reduced tumor viability in patient-derived tumor explants.
Germline homologous recombination deficiency influences TP53 -mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment
Platinum chemotherapy drives DNA damage response gene-mutant clonal hematopoiesis more strongly than PARP inhibitors, an analysis of treatment-associated clone behavior shows. Carrying germline mutations that confer homologous recombination deficiency slowed the expansion of these clones during treatment. The findings separate the mutagenic pressure of the two drug classes and identify germline HR status as a modifier of TP53-mutant clone fitness.
Deciphering the association of spatial landscapes of DCIS with recurrence as invasive breast cancer
Spatial transcriptomics of 49 primary DCIS specimens shows stromal cell gradients, with TREM2+ macrophages and myofibroblastic cancer-associated fibroblasts enriched in tumor-proximal niches. TREM2+ macrophage abundance near tumor nests is associated with recurrence as invasive breast cancer, and ligand-receptor analysis implicates GRN-SORT1, SPP1-CD44, and LGALS9-CD44 signaling between these macrophages and epithelial cells. Findings were validated by multiplex immunostaining.
Methods and resources
RNA isoform-resolved multiplexed sequencing with bioorthogonal barcoding
Bobcodes, bioorthogonal barcodes attached at multiple internal positions along cellular RNAs via acylation and click chemistries, enable multiplexed sequencing that preserves splice junction information. Template switching onto tethered bobcodes during cDNA synthesis occurs with greater than 99% accuracy in species mixing experiments, and priming choice selects between 3'-end counting and full-length isoform capture. A BOB-seq v0.1 drug screen detects transcriptome-wide on- and off-target RNA splicing effects and outperforms existing multiplexing RNA sequencing methods in workflow simplicity, sample-to-sample variability, and barcoding accuracy.
medicalxpress.comBedside blood test can deliver results in under 10 minutes to guide urgent stroke care
A bedside blood test from Aarhus University measures drug concentrations directly in untreated blood in under 10 minutes, versus up to an hour for central laboratory processing. Tested on samples from 52 patients in Denmark and abroad, results matched those of traditional laboratory instruments. The device, costing DKK 30,000-50,000, could let stroke teams quickly check for anticoagulants before giving clot-busting medication, which risks brain hemorrhage in such patients.
Opinion and commentary
The wu wei of brain metastases: When the gift of a pause is also a vulnerability
García-Gómez et al. show that brain-seeding cancer cells enter an MXD4-dependent proliferative pause that restrains MYC and activates protective stress responses, allowing survival under stress before metastatic outgrowth. The pause represents a vulnerability that could be targeted to eradicate micrometastases before clinical relapse. The work appears in Cancer Cell.
China now leads the world in trials for next-gen CAR-T therapies
China now accounts for 82% of the 140 in vivo CAR-T-cell therapies in development globally, according to an analysis by John Wu at Boston Consulting Group and colleagues published last month. Most foundational preclinical work came from the United States and Germany, but China has moved fastest to the clinic, aided by government support and investigator-initiated trials that bypass drug-regulator oversight. The FDA this month approved the first China-developed in vivo CAR-T-cell therapy, for blood cancers, for clinical testing.
In brief
- AI-guided optimization for thermostable mRNA vaccinesnature.com
- ctDNA Release Heterogeneity in Luminal Breast Cancer Revealed by Single-Cell Multi-Omics Spatial Analysisbiorxiv.org
- Experimental mRNA therapy dramatically extends treatment window for acetaminophen overdose in preclinical modelsmedicalxpress.com
- Non-invasive control of gene editing in vivo by photoswitchable Cas12f and focused ultrasoundcell.com
- Structural variation in repeat elements is widespread in normal human tissues and in tumorigenesisbiorxiv.org
- Transcriptional networks underlying tumour plasticity in small-cell lung cancerbiorxiv.org
- Integrated immunopeptidomics and transcriptomics reveal a cancer-restricted non-canonical HLA class I ligandome in medulloblastomabiorxiv.org
- AI and fruit fly tests link BRSK1 gene to rare neurodevelopmental disordermedicalxpress.com
- Accelerated discovery of thermostable mRNA–lipid nanoparticle vaccines using data-efficient AInature.com
Also today
11 events that did not make today's daily, one table per category, one row per event. Open a category to expand.
RegulatoryNMPA Approves Merck's Subcutaneous Pembrolizumab, First PD · Efsitora alfa · NMPA Approves Lilly's Non · Gazyva …6 ▾▴
Filings, acceptances, designations, approvals and withdrawals at a regulator.
- NMPA Approves Merck's Subcutaneous Pembrolizumab, First PDUpdateChina's NMPA has approved Merck's pembrolizumab injection for subcutaneous use (MK-3475A), making it the first subcutaneous PD-1 monoclonal antibody approved in the country. The formulation combines pembrolizumab with berahyaluronidase alfa (ALT-B4), a recombinant human hyaluronidase variant developed and manufactured by South Korea's Alteogen. The approval appeared on the NMPA website on September 28.NMPA
- Efsitora alfaUpdateThe US FDA approved Eli Lilly's once-weekly long-acting insulin Onswik (Efsitora alfa) on September 24, for use with diet and exercise to control high blood sugar in adults with type 2 diabetes. Lilly says the drug cuts more than 300 injections per year compared with once-daily basal insulin. Its marketing application in China has been accepted and is under review.FDA
- NMPA Approves Lilly's NonUpdateChina's NMPA has approved a new indication for Eli Lilly's non-covalent BTK inhibitor pirtobrutinib tablets, which based on clinical trial progress is expected to be first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Pirtobrutinib was first approved in China in October 2024 for third-line mantle cell lymphoma and in February 2026 for second-line CLL/SLL, making this its first move into the first-line setting.NMPA
- GazyvaUpdateFDA
- JuvmoUpdateFDA
- Signal or noise? > Rznomics Cancer Gene Therapy Wins EU Orphan Drug RecommendationUpdate
Deals and financingPrecision Neuroscience · Sofinnova · Tolerance continues thymus · SOLA Biosciences Japan4 ▾▴
Licensing, M&A and financing that did not make the daily.
- Precision NeuroscienceUpdate
- SofinnovaUpdate
- Tolerance continues thymusUpdate
- SOLA Biosciences JapanUpdate
OtherAdicet Bio CAR-T1 ▾▴
Everything else with a concrete event that did not make the daily.
- Adicet Bio CAR-TUpdate